Advertisement
U.S. markets close in 59 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
150.82-3.57 (-2.31%)
As of 02:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close154.39
Open154.48
Bid150.47 x 100
Ask151.51 x 100
Day's Range149.34 - 154.50
52 Week Range143.52 - 218.88
Volume197,100
Avg. Volume863,354
Market Cap18.996B
Beta (5Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALNY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alnylam Pharmaceuticals, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, we explore the state of US auto market; margin of safety erased in US equity market rally; growing pains and growth in US equity market; and EOG Resources, Alnylam, and Pembina.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • Insider Monkey

    30 Biggest Biotechnology Companies in the World

    In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]

  • Zacks

    Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

    Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

  • Reuters

    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

    Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial. Full results of the Phase 2 KARDIA-2 trial, testing the twice-a-year injection zilebesiran, would be presented at the American College of Cardiology Annual Scientific Session in Atlanta on April 6, Roche said in a statement on Tuesday. In July last year, Roche agreed to develop and commercialise Alnylam’s zilebesiran to treat hypertension, the leading cause of cardiovascular disease worldwide.